Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
2024-06-23
CR Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO), which already have blockbusters with their weight loss drugs Zepbound (tirzepatide) and Wegovy (tirzepatide), are likely to dominate the market even if other drugs are approved, according to two Street analysts. Holly Morris, managing director at J.P. Morgan Asset Management focused onContinue Reading